President & COO
Mr. Carmer brings 25 years of diverse leadership experience as a senior executive and chief commercialization officer in the biotech and pharmaceutical industry, with top-tier companies including AstraZeneca, MedImmune, Genentech, Amgen and GlaxoSmithKline. At AstraZeneca, he led the US Specialty Care Division of AstraZeneca with responsibility for the company’s portfolio of specialty care biopharmaceutical products. Prior to AstraZeneca, Mr. Carmer served as Executive Vice President, Commercial Operations of MedImmune. Mr. Carmer was also Vice President, Rheumatology Sales & Marketing for Genentech, where he was responsible for the US launches of Rituxan and ACTEMRA. Prior to Genentech, Mr. Carmer held several leadership roles of increasing responsibility at Amgen, most recently as Executive Director of Global Marketing. Mr. Carmer started his career at GlaxoSmithKline, where he held key roles in Global Brand Management, Business Development, Commercial Operations, Managed Care and Field Sales.
Chief Financial Officer
Mr. Cappeluti has over 30 years of experience in finance and public accounting for private and public companies, with more than 20 of those years spent in the biotech industry working for BioReliance, Human Genome Sciences (HGS), and CoGenesys. As the second employee of HGS in 1992 at the start of the human gene sequencing effort, he held positions of increasing responsibility and served for many years as Vice President of Finance. He has managed both large and small internal financial operations and has participated directly in approximately $4 billion of corporate financing transactions including private and public financings; IPOs; mergers and acquisitions; and real estate transactions. Mr. Cappeluti was part of the team that spun out CoGenesys from HGS in 2006 and was the CFO until the Company was sold to Teva Pharmaceuticals in 2008. Mr. Cappeluti is the President of Noble Life Sciences, serves on the board of O-Traces, Inc., an early stage cancer diagnostics Company, and is a consultant to other life science companies.
Chief Business Officer
Ms. Jones brings more than 25 years of business leadership experience in the biotech and pharmaceutical industries across strategic and operational roles. For five years prior to joining NexImmune Ms. Jones was with Astra Zeneca and its subsidiary MedImmune. From 2013-2015, Ms. Jones was Vice President of Portfolio Strategy and Management at Astra Zeneca, where she played an instrumental role in building a scientifically innovative, diverse portfolio creating new value for the company. Prior to that she served as Vice President of Global Strategic Marketing to shape product plans and prepare MedImmune for multiple launches. Previously, Ms. Jones held multiple leadership roles with increasing responsibility at Genentech, where she worked for 16 years, including Head of Immunology and Ophthalmology in Global Portfolio and Product Strategy, Endocrine and Pulmonary Franchise, and Immunology Business Unit Operations and Pipeline Planning. Ms. Jones also serves in a consulting role for various companies and organizations and serves on the Life Science Panel for Springboard Enterprises focused on start-up companies led by women.
Senior Vice President, Molecular Engineering & Protein Design
Dr. Bednárik has over 30 years experience as a translational scientist and executive specializing in moving promising technologies into product development. He was previously Vice President, Molecular Engineering Unit at Intrexon Corp. where he led a team of scientists developing innovative methods for cellular therapies for cancer. Prior to that, Dr. Bednárik held senior positions at Cardiome Pharma Corporation, Artesian Therapeutics, Inc., and Gene Logic, Inc. and led various projects focused on translational medicine spanning several therapeutic areas including cancer and cardiovascular diseases. Among other accomplishments he created the largest known cardiovascular transcriptomic gene expression database for Gene Logic, Inc. He was also the recipient of a $1.7M DARPA contract in 2006 for the development of a novel non-host method for rapid vaccine manufacture. Earlier in his career, Dr. Bednárik served as a Senior Scientist for Human Genome Sciences (HGS) and completed a post-doctoral fellowship at The Johns Hopkins University Oncology Center.
VP of Preclinical Immunotherapy and Head of Cell Biology
Dr. Oelke is a scientific co-founder of NexImmune and a pioneer of the artificial Antigen Presenting Cell (aAPC) technology. He is also an expert in cellular immunology and T cell research. Dr. Oelke has more than 20 years of research experience in cancer immunotherapy and has a long-standing interest developing methods for antigen-specific stimulation of T cells for therapeutic use. He has numerous peer-reviewed publications and is a co-inventor on more than 15 patents and patent applications describing NexImmune’s proprietary aAPC technology, with additional pending patent applications in related fields of cancer immunotherapy. Prior to joining NexImmune in 2014, Dr. Oelke was, from 2003-2014, on the faculty at Johns Hopkins University, where he still holds an Adjunct Professorship, in the Department of Pathology. Earlier in his career Dr. Oelke who is a chemist by training, received his PhD. in Biology from University of Freiburg, where he first became interested in the critical role of antigen presenting cells and their use in therapy.
Dr. Varela is the Clinical Lead for AIM-ACT at NexImmune. He is a physician scientist with expertise in hematological malignancies, blood and marrow transplantation and translational tumor immunology. He is board certified in Internal Medicine and Hematology and is an Assistant Professor of Oncology at the Medical University of South Carolina. He has extensive experience in the development and execution of clinical trials in acute leukemias and bone marrow transplant. Dr. Varela obtained his MD/PhD at the Medical University of South Carolina and completed his residency in Internal Medicine and fellowship in Hematology at Johns Hopkins Hospital.
Mr. Roemer is a founding senior leadership team member of Roivant Sciences and currently serves as Senior Vice President, Corporate Development. Mr. Roemer previously served as Senior Vice President, Finance & Operations from the company's inception through June 2016 and Chief Financial Officer of Axovant Sciences in 2015. He has raised approximately $1.2 billion in private and public (IPO) capital for Roivant Sciences, Axovant Sciences (NASDAQ:AXON) and Myovant Sciences (NYSE:MYOV) since 2014. Prior to joining Roivant, Mr. Roemer was a Managing Director for the Trout Group, where he provided financing, strategic advisory and investor relations services for life sciences clients and completed over $300 million of fundraising transactions. He previously served as Chief Financial Officer & Treasurer of Zelos Therapeutics and was a Vice President at Pharmasset (acquired by Gilead) from 1999 to 2008. Mr. Roemer was Pharmasset’s first full-time management hire, then responsible for developing the early stage operational infrastructure, fundraising transactions, business development, and investor relations. He raised over $100 million of private and public (IPO) equity for the company. Prior to Pharmasset, Mr. Roemer was a healthcare consultant for Booz-Allen & Hamilton and Deloitte Consulting, and he held various operational roles at Bank of America. He currently serves as a trustee of the Helene Fuld College of Nursing.
President & COO
Mr. Carmer has 27 years of diverse leadership experience in the biopharmaceutical industry that spans activities from early stage clinical development through commercialization and sales. He joined NexImmune in early 2014 and currently serves as the company’s Chief Operating Officer with responsibility for corporate operations, strategy and product development. Before joining NexImmune, Mr. Carmer held senior level positions at AstraZeneca, MedImmune, Genentech, Amgen and GlaxoSmithKline. Most recently, at AstraZeneca he led the US Specialty Care Division with responsibility for the company’s portfolio of oncology and infectious disease products. Prior to AstraZeneca, Mr. Carmer served as the Chief Commercial Officer at MedImmune. Mr. Carmer was also Vice President, Rheumatology Sales & Marketing for Genentech. Prior to Genentech, Mr. Carmer held several leadership roles of increasing responsibility at Amgen, including Executive Director of Global Marketing. Mr. Carmer started his career at GlaxoSmithKline.
Dr. Bertram is the CEO of RegenMed (Cayman) Ltd, a regenerative medicine biotechnology company developing cell-based products with the potential to transform the treatment of kidney diseases leading to renal failure. He currently serves on the Board of Directors for multiple biotechnology companies. As CEO, he led RegenMed Therapeutics from start-up, through organizational building and acquisition. He has been involved in biotechnology company operations for over 10 years. During his 20-year career in large pharma, he held technical leadership and executive roles at Pfizer, SmithKline Beecham Pharmaceuticals, and Procter & Gamble Co. Dr. Bertram has taken small and large molecules, biomaterials and cell based technologies from discovery into clinical development supporting commercialization of products in multiple therapeutic areas. He has been directly involved with the development of eight commercial medical products in multiple jurisdictions and has over 175 scientific publications supporting over 25 commercially-relevant patents. Dr. Bertram has held multiple academic appointments and industrial advisory positions at leading US and European educational institutions.
Mr. D’Angio is an advisor to several biotechnology and pharmaceutical companies and has been in the pharmaceutical industry for more than 30 years, with experience in commercial manufacturing, drug product development, risk management operations and investigational materials supply. From 1998 to 2016 he served as Senior Vice President, Global Head of Technical Operations at Celgene Corporation where he gained extensive cross-functional and technical leadership experience in building and operating a global pharmaceutical manufacturing and supply chain organization. He provided direct leadership in establishing global commercial readiness standards and practices at Celgene, resulting in a number of timely CMC filing and rapid product launches. Mr. D’Angio has a particular commitment to operational excellence and expertise in the management of highly technical cross-functional international teams focused on asset development through filing and commercialization. He has also built teams with long standing and industry leading employee engagement metrics. Earlier in his career, Mr. D’Angio served for 13 years in the manufacturing group at Novartis.
Dr. Spiegel is a physician and oncologist with over 30 years of biopharma experience. At Schering-Plough he was Senior Vice President of Worldwide Clinical Research, prior to becoming Chief Medical Officer and Senior Vice President of Schering-Plough Research Institute in 1998, a position he held until his retirement from Schering-Plough in 2009. He has deep experience in clinical product development, has been involved in filing over 30 New Drug Applications, and has extensive familiarity with regulatory authorities in the US and globally. Dr. Spiegel currently serves as Chairman of the Board of the private company Vidac Pharma and is on the Board of Directors of the public companies Geron Corporation, Edge Therapeutics, and Sucampo Pharmaceuticals. He is a venture advisor to the Israel Biotechnology Fund, Senior Advisor to Warburg Pincus as well as a consultant to various biopharma companies. He is also an Associate Professor at Weill Cornell Medical College. Earlier in his career, Dr. Spiegel was a Research Fellow at the NIH, National Cancer Institute and Assoc. Professor at NYU Cancer Center.
Dr. Yao is the Senior Vice President, R&D and Head of Respiratory, Inflammation & Autoimmunity at MedImmune and leads a cross-functional team dedicated to therapeutic area strategy, prioritization and advancement of the company’s RIA portfolio, a position he has held since 2010. He is an accomplished executive and scientist with more than 20 years of experience in the biotechnology and pharmaceutical industry. At MedImmune, he initiated the MEDI-Wuxi joint venture and currently serves the CEO. Dr. Yao also co-chairs the MedI/AstraZeneca-Amgen collaboration. Prior to joining MedImmune, Dr. Yao led the project team leaders (PTL) group for immunology, neurosciences, virology and metabolism for Genentech and prior to that served as Vice President of Research, acting head of Clinical, and Corporate Officer for Tanox. Earlier in his career Dr. Yao held key roles at Aventis and Amgen. Dr. Yao has authored more than 50 peer reviewed publications and holds over 20 patents and patent applications.
Dr. Yao is a portfolio manager at Arrowmark Partners. Previously, Tony began his investment career in 2002 at Janus Capital Group, where he was focused on making investments in biotechnology, devices, and diagnostic companies at all stages of development. Later, he was assistant portfolio manager on the Janus World Wide fund. He joined Arrowmark Partners in 2012, where he leads their healthcare team and manages the healthcare portfolio. Dr. Yao received an M.D. and Ph.D. (Immunology) from Stanford University.
Dr. Barer has been a Strategic and Board Advisor to NexImmune since 2016. Sol brings more than 30 years of experience in the biotechnology industry. He is the managing partner of SJBarer Consulting and was a founder of Celgene, a global biopharmaceutical company. From 1987 to 2011, Sol led Celgene in various executive roles including president, COO and CEO. He also served as the executive chairman and chairman of the company's board of directors. Sol currently serves as chairman of the board of Centrexion, Edge Therapeutics, Inc., Cerecor, Inc., ContraFect Corp., InspireMD, Inc., Medgenics, Inc. and RestorGenex. He is also on the boards of a number of other biotechnology and pharmaceutical companies including Amicus Therapeutics, Inc., Aegerion Pharmaceuticals, Inc. and Teva Pharmaceuticals. Sol holds a B.S. from Brooklyn College and a Ph.D. in organic chemistry from Rutgers University.
Dr. Bollard is the Director of the Center of Cancer and Immunology Research and National Children’s Hospital and The George Washington University School of Medicine and Health Sciences in Washington, DC. She received her medical degree at the University of Otago in Dunedin, New Zealand and is Board certified both in Pediatrics and Hematology. She worked both in New Zealand and London, England before moving to Baylor College of Medicine (BCM) in 2000 where she was Professor of Pediatrics, Medicine and Immunology and the Director of the Texas Children’s Cancer and Hematology Center Pediatric Lymphoma Program. In August 2013, she moved to Children’s National and The George Washington University where she is Professor of Pediatrics and of Microbiology, Immunology and Tropical Medicine and Director of the Program for Cell Enhancement and Technologies for Immunotherapy (CETI). She is a member of the American Society for Clinical Investigation (ASCI) and is President of the International Society for Cellular Therapy (ISCT). She is on the Board of Directors of the Foundation for the Accreditation of Cellular Therapy (FACT) and Chairs the Non Hodgkin Lymphoma committee of the Children’s Oncology Group. She is an Associate Editor for the journals Blood and Cytotherapy and is a member of the NCI Clinical Oncology Study Section and is a member of the Cellular, Tissues and Gene Therapies Advisory Committee for the Food and Drug Administration (FDA). Her bench and translational research focuses on improving outcomes for patients after hematopoietic stem cell transplantation as well as the development of novel cell therapies for viral diseases and hematologic malignancies.
Dr. Perales is the Deputy Chief of the Adult Bone Marrow Transplantation Service and Director of the Adult Bone Marrow Transplant Fellowship Program at Memorial Sloan Kettering Cancer Center in New York, as well as an Associate Professor of Medicine at Weill Cornell Medical College. He is an internationally recognized leader in the field of hematopoietic stem cell transplantation, serving as a current member of the Board of Directors of Be The Match (National Marrow Donor Program - NMDP) and the American Society of Blood and Marrow Transplantation (ASBMT), where he serves as Secretary and member of the executive committee. He has also held leadership positions and been extensively involved in activities of the Center for International Blood and Marrow Transplant Research (CIBMTR) and Blood and Marrow Transplantation Clinical Trials Network (BMT CTN). His research focuses on clinical and translational investigations of immune-based therapies in patients with cancer. Dr. Perales received his MD from the Free University of Brussels, and completed postdoctoral training at the Tufts Medical Center and Memorial Sloan Kettering Cancer Center.
Dr. Jonathan Schneck is a professor of pathology, medicine and oncology at the Johns Hopkins University School of Medicine and a member of the Johns Hopkins Kimmel Cancer Center. Dr. Schneck received his undergraduate degree from Yeshiva University. He earned his M.D.-Ph.D. in immunology from the Albert Einstein College of Medicine. After completing his degree, he trained in pediatrics at the Children's Hospital National Medical Center in Washington, D.C. From there he worked on the medical staff of the National Institute of Allergy and Immunology at the NIH in Bethesda, and did his postdoctoral training at the Laboratory of Immunology. He joined the Johns Hopkins faculty in 1990 as a junior faculty member. His team pioneered the development of artificial white blood cells, called artificial antigen-presenting cells (aAPCs), which show promise in training animals' immune systems to fight diseases such as cancer. Dr. Schneck was the PI of a research project funded by a $10.3 million NIH grant—the largest basic immunology grant ever received by Johns Hopkins.His research focuses on T cell immunology.
Dr. Yee is Clinical Oncologist and Professor in the Departments of Melanoma Medical Oncology and Immunology, Director of Solid Tumor Cell Therapy, and Co-Director of the Adoptive Cellular Therapy Platform at MD Anderson Cancer Center. He is an elected member of the American Society of Clinical Investigators, recipient of Clinical Translational Scientist Award from Burroughs Wellcome Fund, and co-Leader of the Stand Up to Cancer—American Association for Cancer Research / Cancer Research Institute Immunotherapy Dream Team. Dr. Yee completed his medical degree in Canada followed by an internal medicine residency at Stanford before going on to an oncology fellowship at the University of Washington. He ascended to the position of Professor at the University of Washington and Full Member at the Fred Hutchinson Cancer Research Center. Dr. Yee’s research over the past 20 years has focused on developing immune-based therapies for the treatment of patients with cancer. His specialty, in the area of adoptive cellular therapy, involves the isolation of rare tumor antigen-specific T cells from the peripheral blood, manipulation of immune modulating factors to enhance their effector function and in vivo persistence, and expansion to numbers sufficient for adoptive transfer.